title: CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission.
abstract: Treatment of diffuse large B cell lymphoma (DLBCL) with rituximab, an anti-CD20 monoclonal antibody, has resulted in significantly improved patient responses with longer event-free intervals and higher overall survival rates. However, since rituximab depletes all CD20-expressing cells, including noncancerous B cells, the effects of rituximab on the normal immunity of DLBCL patients under remission need to be examined. Here, we observed that DLBCL patients under remission contained significantly lower frequencies of total B cells, with a significantly overrepresented interleukin (IL)-10-producing B cell (B10) population in the peripheral blood. Further examination confirmed that a large fraction of B10 cells was CD20(-) CD27(hi) plasmablasts, possibly explaining the persistence of B10 cells after R-CHOP treatment. We also observed that the percentage of B10 cells in DLBCL patients in remission gradually reduced during the first year of achieving complete remission, primarily due to the replenishment of non-B10 B cells. Despite this, the percentage of B10 cells in DLBCL patients after 1 year of achieving complete remission was still higher than that in controls. CD4(+) and CD8(+) T cells cocultured with B10-enriched B cells secreted significantly lower levels of proinflammatory cytokines IFN-g and TNF-a, compared to those incubated with B10-depleted B cells. Together, our data observed a long-lasting overrepresentation of B10 cells in DLBCL patients under remission. Whether this change could impact on the overall anti-tumor immunity during remission requires further studies.
authors.affiliation: Department of Haematology, Institute of Haematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
authors.forename: Huiying
authors.initials: H
authors.lastname: Qiu
authors.affiliation: Reproductive Medicine Centre, PLA Army General Hospital, Beijing, China.
authors.forename: Junguo
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Haematology, Liaocheng People's Hospital, Liaocheng, Shandong Province, China.
authors.forename: Zhenjun
authors.initials: Z
authors.lastname: Feng
authors.affiliation: DICAT Biomedical Computation Centre, Vancouver, BC, Canada.
authors.forename: Joanna
authors.initials: J
authors.lastname: Yuan
authors.affiliation: Department of Oncology, Cancer Hospital, Jinan, Shandong Province, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Lu
authors.affiliation: Department of Haematology, Institute of Haematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Hu
authors.affiliation: Department of Haematology, Institute of Haematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Gao
authors.affiliation: Department of Haematology, Institute of Haematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
authors.forename: Shuqing
authors.initials: S
authors.lastname: Lv
authors.affiliation: Department of Haematology, Institute of Haematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
authors.forename: Jianmin
authors.initials: J
authors.lastname: Yang
authors.affiliation: Department of Haematology, Liaocheng People's Hospital, Liaocheng, Shandong Province, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology / Q000627:therapeutic use; D018941:Antigens, CD19 / Q000378:metabolism; D018951:Antigens, CD20 / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D002452:Cell Count; D003520:Cyclophosphamide / Q000494:pharmacology / Q000627:therapeutic use; D015536:Down-Regulation / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000494:pharmacology / Q000627:therapeutic use; D000069283:Rituximab; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000378:metabolism; D014750:Vincristine / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018941:Antigens, CD19; D018951:Antigens, CD20; C571759:R-CHOP protocol; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D016753:Interleukin-10; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: B cell; R-CHOP; diffuse large B cell lymphoma